Novo Nordisk Begins New Study Testing Smaller Doses Of Blockbuster Wegovy – A Look At Some Key Highlights
The 450-person late-stage study began on August 12 and is being conducted across 62 locations in the U.S.…
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly…
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults…
Novo Nordisk launches Wegovy pill in UAE, its first global market
Novo Nordisk launched its Wegovy weight loss pill in the United Arab Emirates on Wednesday, making the Gulf…
Novo Nordisk faces new GLP-1 rival as Eli Lilly’s triple agonist sets weight-loss record
Novo Nordisk faces new GLP-1 rival as Eli Lilly’s triple agonist sets weight-loss record Proactive uses images sourced…
Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…
Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…
Novo Nordisk (NVO) Reports Strong Weight-Loss Results for Higher-Dose Wegovy
Novo Nordisk (NYSE:NVO) unveiled new clinical data on Tuesday showing that a higher 7.2 mg dose of Wegovy…
Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…